“Overcoming Osimertinib Resistance in Lung Cancer: Combination Therapy of Osimertinib and Panobinostat in Lactoferrin-Modified Liposomes”

https://pubmed.ncbi.nlm.nih.gov/38114644

The combination therapy of Osimertinib and Panobinostat delivered via lactoferrin-modified liposomes shows promise in overcoming Osimertinib resistance in non-small cell lung cancer by repolarizing tumor-associated macrophages, suppressing glycolysis and angiogenesis, and reversing epithelial-mesenchymal transition-associated drug resistance.